SIRIUS NEOSIGHT completes €4.4 million financing round to support the development of its therapeutic prediction technology platform in oncology
Sirius Neosight, a company specializing in the isolation of Tumor Circulating Cells (TCCs) and the development of functional tests to predict therapeutic response in oncology, has completed a financing round of 4, 4 million with GO CAPITAL via its GOCA3 seed fund and DEMETER via the Fonds d’Amorçage Industriel Métropolitain (FAIM) Lyon/Saint-Etienne, as well as Evolem, Crédit Agricole Création, Octalfa, Angels Santé, Better Angle and Business Angels specialized in the life sciences sector. This round of financing will enable the company to accelerate the development of its personalized medicine platform, whose ultimate aim is to provide each patient with the most effective cancer treatment.
The fund-raising is also supported by a banking pool and subsidies obtained from Bpifrance, and Sirius is proud to count key clinical players in oncology in its capital: the Centre Léon Bérard in Lyon (via the company Lyon Berard Innovation) and the Institut de Cancérologie de l’Ouest (ICO via ICO Innov).
Sirius Neosight: a patented technology for personalized therapeutic guidance in oncology
Created at the end of 2023, Sirius Neosight is a spin-off from Lyon’s Centre Léon Bérard and Lyon’s academic laboratories: the Centre de Recherche de Cancérologie de Lyon (CRCL: Université Claude Bernard Lyon 1, Inserm, Centre Léon Bérard, CNRS) and the Institut de Chimie et Biochimie Moléculaires et Supramoléculaires (ICBMS: Université Claude Bernard Lyon 1, INSA Lyon, CPE Lyon and CNRS). It is based on research carried out by the teams of Pr Arnaud Vigneron and Pr David Gueyrard, both inventors of the technology and co-founders of the company with Agnès Bastid, CEO of Sirius Neosight. The first technological developments were partly financed by maturation programs supported by PULSALYS and CNRS, then Sirius Neosight was awarded the French Tech Emergence grant from Bpifrance and was a prizewinner in the i-Lab 2024 competition. This initial financial support enabled the company to register the first patents for its membrane fluidity measurement technology, enabling the universal, high-precision isolation of Tumor Circulating Cells from a simple blood sample, and to establish the first proofs of concept for its platform for predicting the efficacy of certain cancer treatments.
Thanks to this first round of funding, Sirius will be able to pursue its ambitions to offer new perspectives in oncology. Over the next 2 years, financial resources will be used to ensure the development of a biological production platform and therapeutic prediction tests enabling the precise orientation of the functional response of targeted therapies for each patient from a simple blood sample. A first clinical demonstrator will be launched in 2025 in partnership with the Centre Léon Bérard in Lyon, and new therapeutic targets are also being developed at the pre-clinical stage.
Sirius Neosight’s operational and clinical development will extend beyond the Rhône-Alpes region from early 2025, with the strategic registration of a secondary operational facility in the heart of the Grand-Ouest region, and the establishment of a close partnership with the Institut de Cancérologie de l’Ouest (ICO) and the Prot’ICO Platform, major players in the fight against cancer.
“We are delighted with the confidence shown by our investors. Their support, and that of the ecosystem in France, is essential to our development, and I’m very proud to work every day alongside the teams committed to the Sirius Neosight project. Based at the Centre Léon Bérard, Sirius Neosight’s ambition is to rapidly bring new solutions to cancer patients, and we are fully committed on a daily basis to alleviating the lives of patients by bringing the hope of better, faster and more effective treatment”
declares Agnès Bastid, President and CEO of Sirius Neosight.
“GO CAPITAL, through its GOCA3 seed fund, is proud to join Sirius Neosight, and to provide financial and strategic support for this new approach to oncology. The solution proposed by Sirius Neosight responds to a real need for a more targeted therapy to best treat all patients. The ambition of the project, backed by a solid team, and the fact that it is based in our western regions, definitely convinced us,” says Leïla Nicolas, Partner specializing in healthcare at GO Capital, and lead investor in the fund-raising.
“Sirius Neosight’s innovation will have a real positive impact on the care of cancer patients, enabling them to benefit directly from the most effective treatment in a personalized care pathway. This project for a biological production and testing platform in Lyon is perfectly in line with the strategy of the Fonds d’Amorçage Industriel Métropolitain (FAIM) managed by Demeter. We’re delighted to be supporting this high-quality team”, says Céline Charvin, Investment Director for Demeter.
About Sirius Neosight: www.sirius-neosight.com
Sirius NeoSight is developing a membrane fluidity measurement technology capable of universally and highly efficiently discriminating and purifying Circulating Tumor Cells (CTCs) present in the bloodstream. Sirius’ technology aims to revolutionize the early detection of relapse, treatment resistance in oncology and the identification of personalized therapies for the most aggressive cancers.
About GO Capital: www.gocapital.fr
GO Capital, an independent asset management company, is a major player in impact investing. With nearly 400 million euros under management, we mainly finance technology leaders in the digital, healthcare and climate transition sectors. Our team of investors, with complementary sector experience, focuses on two verticals: territorial impact and sector impact. We support innovative, responsible projects that create sustainable value at the heart of key territories and sectors. The €47 million GOCA3 fund is a major player in the financing of innovative and technological projects in Western France.
About DEMETER: www.demeter-im.com
Demeter is a major European player in venture capital, development capital and infrastructure investment in the energy and ecological transition. Its funds invest from €1 to €30 million to support companies in the sector at all stages of their development: innovative startups, small and medium-sized enterprises, infrastructure projects. Demeter’s 38-strong team, based in Paris, Lyon, Bordeaux, Madrid and Düsseldorf, manages €1.3 billion and has made 230 investments since 2005. The Lyon team is responsible for managing the Fonds d’Amorçage Industriel Métropolitain (FAIM).
About FAIM Lyon – Saint-Etienne: www.demeter-im.com/faim/
FAIM (Fonds d’Amorçage Industriel Métropolitain) is a seed capital and venture capital fund dedicated to supporting socially and environmentally beneficial productive activities in the Lyon and Saint-Etienne metropolitan areas. Endowed with 70 million euros, it benefits from the support of public players, with the Metropolises of Lyon and Saint-Etienne committing 17 million and 5 million euros respectively, as well as the Banque des Territoires, acting on behalf of the State as part of the France 2030 “Territoires d’innovation” program, with 10 million euros. The fund also mobilizes a large number of private investors, including both industrial and institutional players.
Press contacts:
- Sirius NEOSIGHT : Agnes Bastid – CEO – a.bastid@sirius-ns.com
- GO CAPITAL : Leila NICOLAS – Partner – leila.nicolas@gocapital.fr
- DEMETER : Céline Charvin – celine.charvin@demeter-im.com
- PULSALYS : Sylvain DUC – sylvain.duc@pulsalys.fr
Sirius Neosight Consulting
- Legal advice: Sandra Baverel
- Accounting, tax and employment consultancy: Groupe CANOPEE: Quentin Driguzzi and ODICEO: Agnès Lamoine, Grégoire Varvier and Christophe Vincent
- Intellectual property advice: LAURENT & CHARRAS: Anne Buchet and Esther Maitrejean
Investor relations
- Legal advice: Cabinet FIDAL: Jacques Darbois and Anaïs Abchar
- Accounting, tax and employment advice: Cabinet SECOB: Mathieu Le Barz and Cédric Guegan
- Intellectual property advice: ICOSA: Claire Verschelde and Coline Trichot
- ESG consultancy: GreenFlex – Camille Poutrin
